Apr 08, 2019 - Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
Apr 10, 2019 - AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
Apr 30, 2019 - MRK earnings call for the period ending March 31, 2019.
May 03, 2019 - The index traversed a mixed week, buoyed by encouraging earnings numbers and dragged lower by comments from the Fed Chair.
May 07, 2019 - Top Analyst Reports for Berkshire Hathaway, Merck & Charter Communications
May 08, 2019 - Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.